Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Total Non-Current Liabilities (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Total Non-Current Liabilities for 15 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 20.35% year-over-year to $1.2 billion, compared with a TTM value of $1.2 billion through Dec 2025, up 20.35%, and an annual FY2025 reading of $1.2 billion, up 20.35% over the prior year.
  • Total Non-Current Liabilities was $1.2 billion for Q4 2025 at Neurocrine Biosciences, up from $1.1 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $1.2 billion in Q4 2025 and bottomed at $619.5 million in Q1 2021.
  • Average Total Non-Current Liabilities over 4 years is $837.0 million, with a median of $777.5 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities decreased 5.55% in 2024, then rose 20.35% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $663.0 million in 2021, then skyrocketed by 53.76% to $1.0 billion in 2023, then dropped by 5.55% to $962.8 million in 2024, then grew by 20.35% to $1.2 billion in 2025.
  • Business Quant data shows Total Non-Current Liabilities for NBIX at $1.2 billion in Q4 2025, $1.1 billion in Q3 2025, and $985.4 million in Q2 2025.